{"id":398081,"date":"2020-12-11T07:02:57","date_gmt":"2020-12-11T12:02:57","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=398081"},"modified":"2020-12-11T07:02:57","modified_gmt":"2020-12-11T12:02:57","slug":"immunovia-to-host-a-third-webinar-in-the-series-on-immray-pancan-d-verification-study-and-clinical-use","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-to-host-a-third-webinar-in-the-series-on-immray-pancan-d-verification-study-and-clinical-use\/","title":{"rendered":"Immunovia to Host a Third Webinar in the Series on IMMray\u2122 PanCan-d: Verification Study and Clinical Use"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n LUND, Sweden<\/span>, Dec. 11, 2020<\/span> \/PRNewswire\/ —\u00a0Immunovia AB (publ)\u00a0(“Immunovia”), a near-commercial stage diagnostics company developing ground-breaking antibody-based multiplex microarray technology platform called IMMray\u2122 for the early detection of cancer,\u00a0today announced that the company will be hosting the third webinar in the series on IMMray\u2122 PanCan-d, Immunovia’s test for early detection of pancreatic cancer. This third webinar will cover IMMray\u2122<\/p>\n

PanCan-d verification study results and its clinical use including feedback from experts in pancreatic cancer and pancreatic diseases.<\/p>\n

\n Event Details: Webinar No. 3:\u00a0Immunovia’s IMMray\u2122 PanCan-d Webinar Series Verification Study and Clinical Use <\/b>\n <\/p>\n

\n Date and Time: December 17, 2020<\/span> at 15:00 CET<\/span><\/b>\n <\/p>\n

\n Moderator for the Webinar is CEO Patrik Dahlen<\/span><\/b>\n <\/p>\n

\n Presenters:<\/b>\u00a0Thomas King, MD, PhD, Linda Mellby<\/span>, PhD, VP R&D; and Laura Chirica<\/span>, CCO, PhD, Immunovia<\/p>\n

Immediately after the webinar, the Immunovia team will host a live Q&A session.<\/p>\n

Webinar login and access details will be released on Monday Dec 14, 2020<\/span>.<\/p>\n

\n About the presenters:<\/b>\n <\/p>\n

\n Dr. Thomas King<\/span>, Medical Director, Immunovia<\/i>\n <\/p>\n

Dr. King is a board-certified MD Pathologist with a PhD in Molecular Biology also from Washington University<\/span> in St. Louis<\/span>. Dr. King also has extensive experience as a Laboratory Director in hospital, academic and corporate settings in New England. He has deep expertise in laboratory administration and automation, surgical pathology, and molecular pathology and is currently an Adjunct Associate Professor in the School of Health Professions, Rutgers University<\/span>.<\/p>\n

\n Dr. Linda Mellby<\/span>, VP Research & Development, Immunovia<\/i>\n <\/p>\n

Dr. Mellby received her PhD in Immunotechnology from the Department of Immunotechnology within CREATE Health Translational Cancer Center, Lund<\/span> University, and a MSc in Chemistry Engineering. Mellby has 15+ years of experience in recombinant antibody microarray technology, Immunovia’s IMMray\u2122<\/b>\u00a0platform. Additionally, she has deep knowledge on platform features, technology development, as well as, clinical applications within oncoproteomics and autoimmunity.<\/p>\n

\n Dr. Laura Chirica<\/span>, Chief Commercial Officer, Immunovia<\/i>\n <\/p>\n

Dr. Chirica received her PhD in Biochemistry from Ume\u00e5 University, Sweden<\/span>, and a MSc in Biochemistry and a BSc in Biotechnology. With more than 15+ years of experiences in leading commercial positions within the life science and diagnostics industry, Dr. Chirica contributes with extensive experience in business, organization and strategic development, sales, strategic and tactical marketing, product management and product support. She has a track record of leading and restructuring international sales and marketing organizations, driving business development, champion integration of acquired companies as well as developing branding and market communication platforms.<\/p>\n

For more information, please contact: <\/p>\n

\n

Patrik Dahlen<\/span>, CEO Immunovia<\/p>\n

\n

Email: patrik.dahlen@immunovia.com<\/a><\/p>\n

Tel: +46 73 376 76 64<\/p>\n

About Immunovia <\/p>\n

\n

Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on\u00a0Immunovia’s proprietary test platform called IMMray\u2122.\u00a0Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique “disease biomarker signature”.<\/p>\n

\n

The company was founded in 2007, based on cancer studies and groundbreaking research in the Department of Immuntechnology at Lund<\/span> University and CREATE Health Cancer Center, Sweden<\/span>.<\/p>\n

The first product, IMMray\u2122 PanCan-d, is undergoing clinical evaluation in some of the\u00a0world’s largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1<\/a>\u00a0and is currently in the final validation phase. The company aims for a sales start at the end of Q1 2021 with subsequent commercial testing in Q2.<\/p>\n

When validated, IMMray\u2122 PanCan-d will be the first blood-based test for early diagnosis of pancreatic cancer on the market, with a potential to significantly improve patient survival and outcome.<\/p>\n

Immunovia Dx Laboratories located in Marlborough, Massachusetts<\/span>, USA and Lund, Sweden<\/span> will provide laboratory testing services in two accredited reference laboratories.<\/i><\/p>\n

Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit\u00a0www.immunovia.com<\/a>.<\/p>\n

This information was brought to you by Cision http:\/\/news.cision.com<\/a><\/p>\n

https:\/\/news.cision.com\/immunovia-ab\/r\/immunovia-to-host-a-third-webinar-in-the-series-on-immray–pancan-d–verification-study-and-clinical,c3253308<\/a><\/p>\n

The following files are available for download:<\/p>\n

\n\n\n
\n

https:\/\/mb.cision.com\/Main\/13121\/3253308\/1347348.pdf<\/a><\/span><\/p>\n<\/td>\n

\n

Press release (PDF)<\/span><\/p>\n<\/td>\n<\/tr>\n<\/table>\n<\/div>\n<\/p>\n

\n \"Cision\" View original content:http:\/\/www.prnewswire.com\/news-releases\/immunovia-to-host-a-third-webinar-in-the-series-on-immray-pancan-d-verification-study-and-clinical-use-301191173.html<\/a><\/p>\n

SOURCE Immunovia AB<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire LUND, Sweden, Dec. 11, 2020 \/PRNewswire\/ —\u00a0Immunovia AB (publ)\u00a0(“Immunovia”), a near-commercial stage diagnostics company developing ground-breaking antibody-based multiplex microarray technology platform called IMMray\u2122 for the early detection of cancer,\u00a0today announced that the company will be hosting the third webinar in the series on IMMray\u2122 PanCan-d, Immunovia’s test for early detection of pancreatic cancer. This third webinar will cover IMMray\u2122 PanCan-d verification study results and its clinical use including feedback from experts in pancreatic cancer and pancreatic diseases. Event Details: Webinar No. 3:\u00a0Immunovia’s IMMray\u2122 PanCan-d Webinar Series Verification Study and Clinical Use Date and Time: December 17, 2020 at 15:00 CET Moderator for the Webinar is CEO Patrik Dahlen Presenters:\u00a0Thomas King, MD, PhD, Linda Mellby, PhD, VP R&D; and … <\/p>\n

Continue reading “Immunovia to Host a Third Webinar in the Series on IMMray\u2122 PanCan-d: Verification Study and Clinical Use”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-398081","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nImmunovia to Host a Third Webinar in the Series on IMMray\u2122 PanCan-d: Verification Study and Clinical Use - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-to-host-a-third-webinar-in-the-series-on-immray-pancan-d-verification-study-and-clinical-use\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immunovia to Host a Third Webinar in the Series on IMMray\u2122 PanCan-d: Verification Study and Clinical Use - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire LUND, Sweden, Dec. 11, 2020 \/PRNewswire\/ —\u00a0Immunovia AB (publ)\u00a0(“Immunovia”), a near-commercial stage diagnostics company developing ground-breaking antibody-based multiplex microarray technology platform called IMMray\u2122 for the early detection of cancer,\u00a0today announced that the company will be hosting the third webinar in the series on IMMray\u2122 PanCan-d, Immunovia’s test for early detection of pancreatic cancer. This third webinar will cover IMMray\u2122 PanCan-d verification study results and its clinical use including feedback from experts in pancreatic cancer and pancreatic diseases. Event Details: Webinar No. 3:\u00a0Immunovia’s IMMray\u2122 PanCan-d Webinar Series Verification Study and Clinical Use Date and Time: December 17, 2020 at 15:00 CET Moderator for the Webinar is CEO Patrik Dahlen Presenters:\u00a0Thomas King, MD, PhD, Linda Mellby, PhD, VP R&D; and … Continue reading "Immunovia to Host a Third Webinar in the Series on IMMray\u2122 PanCan-d: Verification Study and Clinical Use"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-to-host-a-third-webinar-in-the-series-on-immray-pancan-d-verification-study-and-clinical-use\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-11T12:02:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO21354&sd=2020-12-11\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-to-host-a-third-webinar-in-the-series-on-immray-pancan-d-verification-study-and-clinical-use\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-to-host-a-third-webinar-in-the-series-on-immray-pancan-d-verification-study-and-clinical-use\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Immunovia to Host a Third Webinar in the Series on IMMray\u2122 PanCan-d: Verification Study and Clinical Use\",\"datePublished\":\"2020-12-11T12:02:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-to-host-a-third-webinar-in-the-series-on-immray-pancan-d-verification-study-and-clinical-use\\\/\"},\"wordCount\":682,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-to-host-a-third-webinar-in-the-series-on-immray-pancan-d-verification-study-and-clinical-use\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO21354&sd=2020-12-11\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-to-host-a-third-webinar-in-the-series-on-immray-pancan-d-verification-study-and-clinical-use\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-to-host-a-third-webinar-in-the-series-on-immray-pancan-d-verification-study-and-clinical-use\\\/\",\"name\":\"Immunovia to Host a Third Webinar in the Series on IMMray\u2122 PanCan-d: Verification Study and Clinical Use - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-to-host-a-third-webinar-in-the-series-on-immray-pancan-d-verification-study-and-clinical-use\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-to-host-a-third-webinar-in-the-series-on-immray-pancan-d-verification-study-and-clinical-use\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO21354&sd=2020-12-11\",\"datePublished\":\"2020-12-11T12:02:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-to-host-a-third-webinar-in-the-series-on-immray-pancan-d-verification-study-and-clinical-use\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-to-host-a-third-webinar-in-the-series-on-immray-pancan-d-verification-study-and-clinical-use\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-to-host-a-third-webinar-in-the-series-on-immray-pancan-d-verification-study-and-clinical-use\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO21354&sd=2020-12-11\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO21354&sd=2020-12-11\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-to-host-a-third-webinar-in-the-series-on-immray-pancan-d-verification-study-and-clinical-use\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immunovia to Host a Third Webinar in the Series on IMMray\u2122 PanCan-d: Verification Study and Clinical Use\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immunovia to Host a Third Webinar in the Series on IMMray\u2122 PanCan-d: Verification Study and Clinical Use - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-to-host-a-third-webinar-in-the-series-on-immray-pancan-d-verification-study-and-clinical-use\/","og_locale":"en_US","og_type":"article","og_title":"Immunovia to Host a Third Webinar in the Series on IMMray\u2122 PanCan-d: Verification Study and Clinical Use - Market Newsdesk","og_description":"PR Newswire LUND, Sweden, Dec. 11, 2020 \/PRNewswire\/ —\u00a0Immunovia AB (publ)\u00a0(“Immunovia”), a near-commercial stage diagnostics company developing ground-breaking antibody-based multiplex microarray technology platform called IMMray\u2122 for the early detection of cancer,\u00a0today announced that the company will be hosting the third webinar in the series on IMMray\u2122 PanCan-d, Immunovia’s test for early detection of pancreatic cancer. This third webinar will cover IMMray\u2122 PanCan-d verification study results and its clinical use including feedback from experts in pancreatic cancer and pancreatic diseases. Event Details: Webinar No. 3:\u00a0Immunovia’s IMMray\u2122 PanCan-d Webinar Series Verification Study and Clinical Use Date and Time: December 17, 2020 at 15:00 CET Moderator for the Webinar is CEO Patrik Dahlen Presenters:\u00a0Thomas King, MD, PhD, Linda Mellby, PhD, VP R&D; and … Continue reading \"Immunovia to Host a Third Webinar in the Series on IMMray\u2122 PanCan-d: Verification Study and Clinical Use\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-to-host-a-third-webinar-in-the-series-on-immray-pancan-d-verification-study-and-clinical-use\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-11T12:02:57+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO21354&sd=2020-12-11","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-to-host-a-third-webinar-in-the-series-on-immray-pancan-d-verification-study-and-clinical-use\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-to-host-a-third-webinar-in-the-series-on-immray-pancan-d-verification-study-and-clinical-use\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Immunovia to Host a Third Webinar in the Series on IMMray\u2122 PanCan-d: Verification Study and Clinical Use","datePublished":"2020-12-11T12:02:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-to-host-a-third-webinar-in-the-series-on-immray-pancan-d-verification-study-and-clinical-use\/"},"wordCount":682,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-to-host-a-third-webinar-in-the-series-on-immray-pancan-d-verification-study-and-clinical-use\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO21354&sd=2020-12-11","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-to-host-a-third-webinar-in-the-series-on-immray-pancan-d-verification-study-and-clinical-use\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-to-host-a-third-webinar-in-the-series-on-immray-pancan-d-verification-study-and-clinical-use\/","name":"Immunovia to Host a Third Webinar in the Series on IMMray\u2122 PanCan-d: Verification Study and Clinical Use - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-to-host-a-third-webinar-in-the-series-on-immray-pancan-d-verification-study-and-clinical-use\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-to-host-a-third-webinar-in-the-series-on-immray-pancan-d-verification-study-and-clinical-use\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO21354&sd=2020-12-11","datePublished":"2020-12-11T12:02:57+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-to-host-a-third-webinar-in-the-series-on-immray-pancan-d-verification-study-and-clinical-use\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-to-host-a-third-webinar-in-the-series-on-immray-pancan-d-verification-study-and-clinical-use\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-to-host-a-third-webinar-in-the-series-on-immray-pancan-d-verification-study-and-clinical-use\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO21354&sd=2020-12-11","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO21354&sd=2020-12-11"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-to-host-a-third-webinar-in-the-series-on-immray-pancan-d-verification-study-and-clinical-use\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Immunovia to Host a Third Webinar in the Series on IMMray\u2122 PanCan-d: Verification Study and Clinical Use"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/398081","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=398081"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/398081\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=398081"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=398081"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=398081"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}